S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NASDAQ:HOOK

Hookipa Pharma - HOOK Stock Forecast, Price & News

$1.68
+0.09 (+5.66%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.57
$1.71
50-Day Range
$1.36
$1.89
52-Week Range
$1.25
$7.30
Volume
287,243 shs
Average Volume
286,834 shs
Market Capitalization
$91.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.83

Hookipa Pharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
425.8% Upside
$8.83 Price Target
Short Interest
Healthy
4.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.19mentions of Hookipa Pharma in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.56) to ($1.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

473rd out of 1,135 stocks

Pharmaceutical Preparations Industry

237th out of 557 stocks

HOOK stock logo

About Hookipa Pharma (NASDAQ:HOOK) Stock

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Wall Street Analyst Weigh In

Separately, SVB Leerink dropped their price target on shares of Hookipa Pharma from $4.00 to $3.00 and set an "outperform" rating on the stock in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Hookipa Pharma has a consensus rating of "Moderate Buy" and a consensus target price of $8.83.

Hookipa Pharma Price Performance

NASDAQ:HOOK traded up $0.09 during trading hours on Friday, hitting $1.68. The company's stock had a trading volume of 287,243 shares, compared to its average volume of 286,834. Hookipa Pharma has a 12 month low of $1.25 and a 12 month high of $7.30. The company's 50 day simple moving average is $1.63 and its two-hundred day simple moving average is $1.67. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.48 and a quick ratio of 5.48.

Hookipa Pharma (NASDAQ:HOOK - Get Rating) last announced its quarterly earnings results on Monday, May 16th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.28). The company had revenue of $1.45 million during the quarter, compared to the consensus estimate of $21.05 million. Hookipa Pharma had a negative return on equity of 65.62% and a negative net margin of 632.09%. During the same quarter in the prior year, the firm earned ($0.53) earnings per share. Equities research analysts anticipate that Hookipa Pharma will post -1.56 earnings per share for the current fiscal year.

Receive HOOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter.

HOOK Stock News Headlines

HOOKIPA Announces Executive Leadership Changes
Recap: HOOKIPA Pharma Q1 Earnings
See More Headlines
Receive HOOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter.

HOOK Company Calendar

Last Earnings
5/16/2022
Today
8/13/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HOOK
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.83
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+425.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-75,660,000.00
Net Margins
-632.09%
Pretax Margin
-523.53%

Debt

Sales & Book Value

Annual Sales
$18.45 million
Book Value
$2.87 per share

Miscellaneous

Free Float
52,176,000
Market Cap
$91.88 million
Optionable
Not Optionable
Beta
0.85














HOOK Stock - Frequently Asked Questions

Should I buy or sell Hookipa Pharma stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HOOK shares.
View HOOK analyst ratings
or view top-rated stocks.

What is Hookipa Pharma's stock price forecast for 2022?

6 analysts have issued 12-month target prices for Hookipa Pharma's shares. Their HOOK share price forecasts range from $3.00 to $16.00. On average, they predict the company's stock price to reach $8.83 in the next twelve months. This suggests a possible upside of 425.8% from the stock's current price.
View analysts price targets for HOOK
or view top-rated stocks among Wall Street analysts.

How have HOOK shares performed in 2022?

Hookipa Pharma's stock was trading at $2.33 at the beginning of the year. Since then, HOOK shares have decreased by 27.9% and is now trading at $1.68.
View the best growth stocks for 2022 here
.

When is Hookipa Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our HOOK earnings forecast
.

How were Hookipa Pharma's earnings last quarter?

Hookipa Pharma Inc (NASDAQ:HOOK) posted its earnings results on Monday, May, 16th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.28. The business earned $1.45 million during the quarter, compared to the consensus estimate of $21.05 million. Hookipa Pharma had a negative net margin of 632.09% and a negative trailing twelve-month return on equity of 65.62%. During the same quarter last year, the firm earned ($0.53) earnings per share.

What other stocks do shareholders of Hookipa Pharma own?

When did Hookipa Pharma IPO?

(HOOK) raised $100 million in an initial public offering on Thursday, April 18th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.

What is Hookipa Pharma's stock symbol?

Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."

Who are Hookipa Pharma's major shareholders?

Hookipa Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.17%), Northern Trust Corp (0.11%), Group One Trading L.P. (0.00%), Virtu Financial LLC (0.05%), Concourse Financial Group Securities Inc. (0.00%) and Sculptor Capital LP (0.00%). Insiders that own company stock include Anders Lilja, Igor Matushansky, Klaus Orlinger and Sofinnova Capital Vi Fcpr.
View institutional ownership trends
.

How do I buy shares of Hookipa Pharma?

Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hookipa Pharma's stock price today?

One share of HOOK stock can currently be purchased for approximately $1.68.

How much money does Hookipa Pharma make?

Hookipa Pharma (NASDAQ:HOOK) has a market capitalization of $91.88 million and generates $18.45 million in revenue each year. The company earns $-75,660,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.

How can I contact Hookipa Pharma?

Hookipa Pharma's mailing address is 350 FIFTH AVENUE 72ND FLOOR SUITE 7240, NEW YORK NY, 10118. The official website for the company is www.hookipapharma.com. The company can be reached via phone at 431-890-6360, via email at ir@hookipapharma.com, or via fax at 43-1890-636-0399.

This page (NASDAQ:HOOK) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.